ArticlePLOS global public health2025
Low HIV-risk aligned discontinuation among HIV pre-exposure prophylaxis users within public HIV clinics in Kenya: A mixed method study.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04424524 (An Implementation Project to Improve the Efficiency of PrEP Delivery in Public Health HIV Care Clinics in Kenya), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Implementation Project to Improve the Efficiency of PrEP Delivery in Public Health HIV Care Clinics in Kenya
Who cites it
1 citing paper in PubMed.
- Integrating oral pre-exposure prophylaxis delivery in primary care family planning clinics: a pragmatic, stepped-wedge, cluster-randomised trial.The Lancet. Primary care · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Adherence to oral HIV pre-exposure prophylaxis (PrEP) is crucial for its effectiveness, however, studies have shown that PrEP use wanes within the first six months. We sought to understand reasons for discontinuation among individuals previously accessing PrEP from HIV clinics. Between November 2020 - January 2023, we conducted a mixed methods sub-study within a programmatic study to improve the efficiency of PrEP delivery in four public HIV clinics in Kenya (ClinicalTrials.gov number NCT04424524). We used random simple stratification to select individuals who had discontinued PrEP and completed surveys; we purposively sampled a subset of participants for in-depth interviews. Quantitative data were analyzed descriptively; qualitative data were analyzed thematically guided by the socio-ecological model. Overall, 300 participants completed surveys; median age was 35 years (interquartile range 28-43), 61% were female and 57% were married/cohabiting. Majority (76%) discontinued PrEP because of low perceived risk of HIV acquisition. Nearly half (43.7%) reported not being at risk, 23% had separated from their partners or had partners who were virally suppressed (6%), 3.3% were discontinued by healthcare providers. Other reasons for discontinuation were PrEP use concerns (15.6%) including concerns about side effects (8.7%) and daily pill burden (6%). Accessibility challenges (4%), and opportunity costs such as fear of missing/losing work (1%) were reported less frequently. Similarly in qualitative interviews, participants (n=30) reported PrEP discontinuation was mainly driven by perceived low HIV risk due to changes in relationship dynamics (separation/partner relocation), partner achieving viral suppression for those in serodifferent partnerships and reduced sexual activity (individual and interpersonal factors). Other themes included perceived HIV/PrEP stigma (community factors), frequency of clinic visits and long wait times (structural/institutional factors). PrEP discontinuation was mainly associated with perceived low HIV risk in this study population. Prevention-effective adherence counselling is essential in supporting individuals to correctly assess HIV risk to inform appropriate discontinuation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.